Oruka Therapeutics’ (ORKA) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Tuesday morning,RTT News reports. The brokerage currently has a $40.00 price target on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

A number of other analysts have also issued reports on the company. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price for the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Thursday, October 31st. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target for the company. Finally, Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

ORKA stock opened at $20.50 on Tuesday. The firm has a market capitalization of $24.81 million, a price-to-earnings ratio of -3.55 and a beta of 0.87. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88. The company’s 50 day moving average price is $26.36.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter worth $343,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics during the third quarter worth about $1,037,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at $2,013,000. Janus Henderson Group PLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $5,840,000. Finally, Redmile Group LLC acquired a new position in Oruka Therapeutics in the third quarter valued at about $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.